Fosun Pharmaceutical_ 1Q25 Behind; Innovative Transition Ongoing
2025-05-06 02:28
更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 M Update 1Q25 Behind; Innovative Transition Ongoing Reaction to earnings April 30, 2025 04:07 AM GMT Fosun Pharmaceutical | Asia Pacific Morgan Stanley Asia Limited+ Yanru Tao Equity Analyst Yanru.Tao@morganstanley.com +852 3963-1041 Alexis Yan, CFA Equity Analyst Alexis.Yan@morganstanley.com +852 2239-7953 Impact to our thesis Financial results versus consensus Direction of next 12-month Unchanged Meaningful shortfall Meaningful revision lower consensus EPS Key Takeaways 1Q25 R ...